Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

The restoration of differential activity is fundamental for complex retinal response to light stimulation, which allows for more natural vision." "In pre-clinical models of retinitis pigmentosa ...

In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...

Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

Ocugen (OCGN) announced that the European Commission has provided a positive opinion from the EMA’s, or European Medicines Agency’s, Committee ...